Kidswell Bio Corporation Logo

Kidswell Bio Corporation

Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.

4584 | T

Overview

Corporate Details

ISIN(s):
JP3386460004
LEI:
Country:
Japan
Address:
中央区新川一丁目2番12号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kidswell Bio Corporation is a biopharmaceutical company focused on the research and development of innovative pharmaceuticals and therapeutics, with a particular emphasis on pediatric diseases. Formerly known as Gene Techno Science and founded in 2001, the company's operations are centered around three core business segments: Biosimilars, leveraging its expertise in cell line development and CMC; New Biologics, which includes the development of novel antibodies for cancer and eye diseases; and Cell Therapy, which pioneers next-generation cellular medicines based on SHED (Stem cells from Human Exfoliated Deciduous teeth) to address unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 07:44
Registration Form
確認書
Japanese 8.1 KB
2025-11-14 07:43
Interim Report
半期報告書-第26期(2025/04/01-2026/03/31)
Japanese 189.9 KB
2025-06-30 08:33
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2025-06-27 08:36
Registration Form
確認書
Japanese 8.0 KB
2025-06-27 08:35
Governance Information
内部統制報告書-第25期(2024/04/01-2025/03/31)
Japanese 22.2 KB
2025-06-27 08:33
Annual Report
有価証券報告書-第25期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2025-03-31 09:16
Regulatory News Service
臨時報告書
Japanese 18.2 KB
2024-12-26 07:56
Registration Form
有価証券届出書(組込方式)
Japanese 543.7 KB
2024-11-14 07:50
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-14 07:47
Interim Report
半期報告書-第25期(2024/04/01-2025/03/31)
Japanese 185.0 KB
2024-06-27 09:12
Post-Annual General Meeting Information
臨時報告書
Japanese 22.5 KB
2024-06-27 09:11
Governance Information
内部統制報告書-第24期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-27 09:11
Registration Form
確認書
Japanese 8.1 KB
2024-06-27 09:10
Annual Report
有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-06-07 08:39
Regulatory News Service
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all Kidswell Bio Corporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kidswell Bio Corporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kidswell Bio Corporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

kainos loboratories,inc Logo
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
Kairos Pharma, LTD. Logo
Develops novel oncology therapies to reverse drug resistance and immune suppression.
United States of America
KAPA
KAKEN PHARMACEUTIAL CO., LTD. Logo
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
KALA BIO, Inc. Logo
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
Kalaris Therapeutics, Inc. Logo
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom
KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN

Talk to a Data Expert

Have a question? We'll get back to you promptly.